

Identification of rare-disease genes from RNA-seq of diverse undiagnosed cases using large control cohorts

Laure Frésard¹, C. Smail², K.S. Smith¹, N.M. Ferraro², N.A. Teran³, K. Kernohan⁴, D. Bonner⁵, X. Li¹, S. Marwaha⁵, Z. Zappala^{1,3}, B. Balliu¹, J.R. Davis^{1,2}, B. Liu⁶, C.J. Prybol³, J.N. Kohler⁵, D.B. Zastrow⁵, D.G. Fisk⁷, M.E. Grove⁷, J.M. Davidson⁵, T. Hartley⁴, R. Joshi⁷, B.J. Strober⁸, S. Utiramerur⁶, Care4Rare Canada Consortium⁴, Undiagnosed Disease Network⁹, L. Lind¹⁰, E. Ingelsson^{11,12}, A. Battle^{8,13}, G. Bejerano¹⁴, J.A. Bernstein^{11,15}, E.A. Ashley^{3,11}, K. Boycott⁴, J.D. Merker^{1,7,16}, M.T. Wheeler^{5,11}, S.B. Montgomery^{1,3}

¹ Department of Pathology, School of Medicine, Stanford, CA, USA; ² Biomedical Informatics Program, Stanford, CA, USA; ³ Department of Genetics, School of Medicine, Stanford, CA, USA; ⁴ Children's Hospital of Eastern Ontario, Ontario, Canada; ⁵ Stanford Center for Undiagnosed Diseases, Stanford, CA, USA; ⁶ Department of Biology, Stanford, CA, USA; ⁷ Stanford Medicine Clinical Genomics Program, Stanford, CA, USA; ⁸ Department of Biomedical Engineering, John Hopkins University, MD, USA; ⁹ NIH Undiagnosed Diseases Network, Bethesda, MD, USA; ¹⁰ Department of Medical Sciences, Uppsala University, Sweden; ¹¹ Department of Medicine, School of Medicine, Stanford, CA, USA; ¹² Stanford Cardiovascular Institute Stanford, CA, USA; ¹³ Department of Computer Science, John Hopkins University, Baltimore, MD, USA; ¹⁴ Department of Computer Science, Stanford, CA, USA; ¹⁵ Department of Pediatrics, School of Medicine, Stanford, CA, USA; ¹⁶ Department of Pathology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

Background

Investigating rare diseases is of great importance

For science

- Reveals biochemical pathways
- Helps genome annotation and interpretation
- Better understanding of Mendelian diseases

For families

- Identification of the causal gene
- Family planning
- Drug development
- Treatment/disease management


RNA-based applications show considerable promise

- Exome sequencing alone is insufficient in 68% of rare disease diagnosis¹
- RNA-seq has shown diagnostic utility in specific tissues and diseases^{2,3}
- We can observe the consequences of both coding and non-coding variants in gene expression and splicing events



The generalizability of this approach to diverse Mendelian diseases has yet to be evaluated

→ To assess RNA-seq from blood as general diagnostic tool, we sought to evaluate it for rare diseases of different pathophysiologies.

Blood transcriptome as a surrogate for pathological tissue



Material and Methods




Outlier patterns of cases

Expression outlier


→ Case outliers are enriched for genes that are sensitive to Loss of Function variation

Splicing outlier

→ Significant increase in number deleterious rare variants in the gene when filtering for outliers with a rare variant in a gene relevant to the disease phenotype




Aberrant transcripts can be detected as outliers



→ On average we find a few hundreds candidate genes to a handful depending on stringency of the Z-score threshold


Filtering outliers reduces the number of candidate genes



→ By filtering outliers for relevant criteria, we are able to reduce drastically the number of candidates

Combining information helps pinpoint the causal gene

Solved case #1 (Neurology): Expression outlier




→ Relevant filters allow to narrow down a list of over 2,000 genes to a handful that contain the causal gene.

→ In both presented cases, the causal genes are ranked **first** in term of Z-score after filters

→ Those cases belong to the neurology category

Solved case #2 (Neurology): Splicing outlier



References

- 1 Zappala and Montgomery, *Hum. Hered.* 2016
- 2 Cummings et al., *Sci. Transl. Med.* 2017
- 3 Kremer et al., *Nat. Commun.* 2017
- 4 Battle et al, *Genome Res.* 2014
- 5 Lind et al, *Arterioscler. Thromb. Vasc. Biol.* 2005
- 6 Kernohan et al., *Hum. Mutat* 2017
- 7 Merker et al., *Genet. Med* 2017

Acknowledgments

- Care4Rare
- the Undiagnosed Disease Network
- the Stanford Clinical Genomics Service
- Montgomery lab

Conclusions

- **Blood** can be an effective surrogate for the investigation of rare diseases by RNA-seq
- Across our cohort, we observed that RNA-seq yields a **8.5% diagnostic rate**
- RNA-seq can be used to **confirm the impacts** of known mutations and **discover new mutations** affecting expression^{6,7}